AstraZeneca – Page 5

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefit in Muscle-Invasive Bladder Cancer, Raises Questions on FDA Approval for Perioperative Design

7 months ago talkbio0Tagged Approved, AstraZeneca, Benefit, Continuance of life, Imfinzi, MIBC, muscle-invasive bladder cancer, trial design, United States Food and Drug Administration

AstraZeneca, Imfinzi, durvalumab, muscle-invasive bladder cancer, MIBC, perioperative trial design, FDA approval, survival benefit

ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer

7 months ago talkbio0Tagged Advanced phase, AstraZeneca, durvalumab, ESMO24, Imfinzi, Imjudo, Liver and Intrahepatic Biliary Tract Carcinoma, Liver carcinoma, Overall Survival, tremelimumab

AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

7 months ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

8 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study